As of 2025-06-30, the Relative Valuation of Cardiff Oncology Inc (CRDF) is (14.87) USD. This relative valuation is based on P/E multiples. With the latest stock price at 3.15 USD, the upside of Cardiff Oncology Inc based on Relative Valuation is -572.1%.
The range of the Relative Valuation is (12.10) - (16.58) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 15.0x - 22.6x | 18.8x |
| Forward P/E multiples | 16.5x - 26.9x | 21.7x |
| Fair Price | (12.10) - (16.58) | (14.87) |
| Upside | -484.2% - -626.4% | -572.1% |
| Date | P/E |
| 2025-06-26 | -4.30 |
| 2025-06-25 | -4.22 |
| 2025-06-24 | -4.36 |
| 2025-06-23 | -4.30 |
| 2025-06-20 | -4.22 |
| 2025-06-18 | -4.11 |
| 2025-06-17 | -5.04 |
| 2025-06-16 | -5.26 |
| 2025-06-13 | -5.19 |
| 2025-06-12 | -5.16 |
| 2025-06-11 | -5.26 |
| 2025-06-10 | -5.86 |
| 2025-06-09 | -5.26 |
| 2025-06-06 | -5.28 |
| 2025-06-05 | -4.93 |
| 2025-06-04 | -4.93 |
| 2025-06-03 | -4.78 |
| 2025-06-02 | -4.56 |
| 2025-05-30 | -4.64 |
| 2025-05-29 | -4.55 |
| 2025-05-28 | -4.34 |
| 2025-05-27 | -4.22 |
| 2025-05-23 | -4.13 |
| 2025-05-22 | -3.92 |
| 2025-05-21 | -3.95 |
| 2025-05-20 | -4.18 |
| 2025-05-19 | -3.96 |
| 2025-05-16 | -3.83 |
| 2025-05-15 | -3.74 |
| 2025-05-14 | -3.64 |
| 2025-05-13 | -3.70 |
| 2025-05-12 | -3.74 |
| 2025-05-09 | -3.62 |
| 2025-05-08 | -3.58 |
| 2025-05-07 | -3.39 |
| 2025-05-06 | -3.47 |
| 2025-05-05 | -3.65 |
| 2025-05-02 | -3.84 |
| 2025-05-01 | -3.69 |
| 2025-04-30 | -3.73 |
| 2025-04-29 | -3.79 |
| 2025-04-28 | -4.02 |
| 2025-04-25 | -3.92 |
| 2025-04-24 | -3.95 |
| 2025-04-23 | -4.00 |
| 2025-04-22 | -4.15 |
| 2025-04-21 | -3.84 |
| 2025-04-17 | -3.88 |
| 2025-04-16 | -3.83 |
| 2025-04-15 | -4.00 |